Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi to Cut 1,500-2,000 Jobs in France - Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2012 | 02:11pm CEST

French pharmaceutical giant Sanofi SA (SAN.FR, SNY) will disclose cuts of between 1,500 and 2,000 jobs in France on Sept. 25, French newspaper Le Figaro reported Saturday, without citing sources.

The company plans to reduce its 28,000 payroll in France mainly through attrition, the newspaper said.

In July, Sanofi had said it planned to cut jobs at two French units in a bid to preserve the company's profitability, which has been put at risk by recent patent expirations and the economic recession in most of Europe. The company had said it would detail the job cuts in September.

At the time, French Industry Minister Arnaud Montebourg had criticized the company and said he wouldn't tolerate when profitable companies slash jobs.

A Sanofi spokesman didn't return a phone call seeking comments.

Newspaper Web site: http://www.lefigaro.fr

Write to Inti Landauro at inti.landauro@dowjones.com.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07/23 SANOFI : Judicial Panel on Multidistrict Litigation Issues Order on Taxotere
07/22 SANOFI : Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Tre..
07/22 SANOFI : MSDs Lantus biosimilar given conditional FDA approval
07/22 SANOFI INDIA : Competition Commission of India rejects unfair business practices..
07/21 SANOFI : Annual fundraiser honors nonprofits
07/21 SANOFI : Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupil..
07/21 SANOFI : and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) t..
07/20 SANOFI : Disclosure of trading in own shares
07/20 AUROBINDO PHARMA : Gets nod to sell kidney drug
07/20 SANOFI : 2017-2018 Flu Vaccine on Its Way to US
More news
News from SeekingAlpha
07/23 Tracking Ken Fisher'S Fisher Asset Management Portfolio - Q2 2017 Update
07/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 23, 2017
07/21 Sirukumab's Panel And U.S. Decision For Medicines Company
07/21 European advisory group backs approval of 11 new meds
07/20 FDA tentatively OKs Merck's biologic basal insulin
Financials (€)
Sales 2017 36 540 M
EBIT 2017 9 540 M
Net income 2017 7 939 M
Debt 2017 4 751 M
Yield 2017 3,74%
P/E ratio 2017 12,98
P/E ratio 2018 16,86
EV / Sales 2017 2,94x
EV / Sales 2018 2,82x
Capitalization 102 777 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,1 €
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.01%119 827
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303